RZ-520 / Rezubio Pharmaceuticals - LARVOL DELTA

Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases (GlobeNewswire) - "Rezubio today announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the US FDA and Chinese NMPA. This trial evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of RZ-520 in healthy volunteers. RZ-520 is the second clinical-stage asset developed using Rezubio's proprietary Membrane-Anchored Drug Design (MADD) platform."

IND • Trial status • Respiratory Diseases